GHK-Cu dosage research

No rigorously established human systemic half-life for GHK-Cu is available in the reviewed record. Study concentrations describe experiments; they cannot supply a personal amount, interval, or injection schedule.
Half life of GHK Cu
A half-life describes the time required for a measured amount or concentration to fall by half under defined conditions. A useful value must identify the substance, route, and measurements over time. Free GHK and the copper complex cannot be treated as the same substance for that purpose.
The frequently cited 1997 study by Endo and colleagues examined rats given free GHK intravenously. Researchers followed the peptide and its breakdown product, histidyl-lysine, in plasma. The study documented rapid metabolism in that animal setting.
It did not establish a human half-life for GHK-Cu. Quoting a short number without the species and peptide identity makes the evidence sound more complete than it is. A value repeated in community discussions remains unvalidated if the required human measurements are absent.
Likewise, copper retained in skin cannot be used to calculate how quickly intact GHK-Cu leaves a living person's circulation. Local retention and systemic elimination answer different questions.
Amounts used in named experiments
In Maquart and colleagues’ fibroblast study, researchers tested GHK-Cu at concentrations from 10^-12 to 10^-9 M in culture medium. The notation M means moles per liter, a way to express concentration. The cells were exposed directly to the material in their laboratory environment.
In Lee and colleagues’ human hair trial, researchers studied topical formulations containing the GHK and 5-aminolevulinic acid combination at 50 mg/mL and 100 mg/mL for six months. Those concentrations describe that combination study, rather than standalone GHK-Cu or an injection preparation.
These figures cannot be placed on one simple dosing scale. A culture-medium concentration and a finished topical formulation differ in composition, exposure, and purpose. Converting between them would require assumptions that the studies did not test.
There is no FDA-approved GHK-Cu medicine with a label that establishes a systemic dosing schedule. The record also contains no completed Phase 2 or Phase 3 systemic GHK-Cu trial that supplies such a regimen.
Route and formulation change exposure
The human skin penetration experiment used pieces of skin in a laboratory and measured copper after a topical preparation was applied. It found both movement through skin and retention within it. Those measurements do not establish the distribution of intact GHK-Cu in a living person.
Researchers have also explored lipid carriers for topical GHK-Cu. A carrier can affect stability and access to tissue. A result for one carrier cannot define the behavior of every product containing a similarly named ingredient.
Animal systemic experiments add other routes, but species differences remain. None of these studies supplies a validated way to translate a research amount into personal use. A more detailed measurement of one preparation is valuable precisely because it keeps the preparation and route identifiable.
The broader research page considers why repeated systemic exposure needs its own safety evidence. The distinction is especially important when a claim combines topical experience with findings from a different route.
Questions for a prescribing discussion
A prescriber has to consider a person's history alongside the intended outcome and the evidence for the proposed preparation. Published concentrations cannot make that judgment. Nor can a community schedule establish that a preparation is appropriate or that repeated exposure has been studied adequately.
Useful discussion points include whether the evidence concerns the same substance and route, what human outcomes have been measured, how uncertainty will be explained, and what information would change the decision. These are questions about evidence and care, rather than a suggested protocol.
On the FDA's dated safety-risk page, the injectable GHK-Cu entry retains concerns about possible immune responses, aggregation, and impurities despite the withdrawal of its nomination. A prescription does not supply the missing human pharmacokinetic data or convert a compounded medicine into an approved drug.
For skin-specific concerns, the effects page separates irritation reports from pigment experiments. Both deserve context before an amount from a study is treated as more informative than it really is.